Publications by authors named "A T Corsa"
The study aimed to evaluate the effects of baseline hepatitis C virus (HCV) nonstructural protein 5A (NS5A) resistance-associated substitutions (RASs) on sustained virologic response to ledipasvir (LDV)-containing regimens in the absence of sofosbuvir (SOF) in patients with HCV genotype (GT) 1 infection across 6 phase 2 clinical studies. We analysed data from 1103 patients who received either LDV + vedroprevir (NS3 protease inhibitor) + tegobuvir (NS5B inhibitor) ± ribavirin or LDV + ribavirin + pegylated interferon. Population sequencing of HCV NS5A was performed at baseline and at virologic failure from patient plasma samples.
View Article and Find Full Text PDFA major hurdle in the long-term treatment of chronic hepatitis B (CHB) patients is to maintain viral suppression in the absence of drug resistance. To date, no evidence of resistance to tenofovir disoproxil fumarate (TDF) has been observed. A cumulative evaluation of CHB patients who qualified for resistance surveillance over 8 years of TDF treatment was conducted.
View Article and Find Full Text PDFIn Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir.
Antimicrob Agents Chemother
January 2016
Ledipasvir (LDV; GS-5885), a component of Harvoni (a fixed-dose combination of LDV with sofosbuvir [SOF]), is approved to treat chronic hepatitis C virus (HCV) infection. Here, we report key preclinical antiviral properties of LDV, including in vitro potency, in vitro resistance profile, and activity in combination with other anti-HCV agents. LDV has picomolar antiviral activity against genotype 1a and genotype 1b replicons with 50% effective concentration (EC50) values of 0.
View Article and Find Full Text PDFArticle Synopsis
- A study evaluated the effectiveness of combining tenofovir disoproxil fumarate (TDF) with peginterferon α-2a (peginterferon) in achieving loss of hepatitis B surface antigen (HBsAg) among patients with chronic hepatitis B over several treatment durations.
- At week 72, 9.1% of patients who received the combination treatment for 48 weeks (group A) showed HBsAg loss, significantly outperforming those on TDF alone (group C) and peginterferon alone (group D).
- The study concluded that the combination therapy resulted in higher rates of HBsAg loss, regardless of hepatitis B e antigen status, while adverse event rates were similar across different treatment groups
Background And Aims: HBsAg loss is a desired, but rare, treatment-induced clinical endpoint in chronic hepatitis B (CHB). Few studies have evaluated viral factors contributing to HBsAg loss.
Methods: This study evaluated baseline interpatient sequence diversity across the HBV genome in tenofovir disoproxil fumarate-treated patients who lost HBsAg and compared it to that of control patients with high HBsAg levels throughout therapy.